Proteogenomic identification of an immunogenic antigen derived from human endogenous retrovirus in renal cell carcinoma.
Antigen presentation
Cancer immunotherapy
Immunology
Oncology
T cells
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
22 08 2023
22 08 2023
Historique:
received:
06
12
2022
accepted:
11
07
2023
medline:
23
8
2023
pubmed:
22
8
2023
entrez:
22
8
2023
Statut:
epublish
Résumé
CD8+ T cells can recognize tumor antigens displayed by HLA class I molecules and eliminate tumor cells. Despite their low tumor mutation burden, immune checkpoint blockade (ICB) is often beneficial in patients with renal cell carcinoma (RCC). Here, using a proteogenomic approach, we directly and comprehensively explored the HLA class I-presenting peptidome of RCC tissues and demonstrated that the immunopeptidomes contain a small subset of peptides derived from human endogenous retroviruses (hERV). A comparison between tumor and normal kidney tissues revealed tumor-associated hERV antigens, one of which was immunogenic and recognized by host tumor-infiltrating lymphocytes (TIL). Stimulation with the hERV antigen induced reactive CD8+ T cells in healthy donor-derived (HD-derived) peripheral blood mononuclear cells (PBMC). These results highlight the presence of antitumor CD8+ T cell surveillance against hERV3895 antigens, suggesting their clinical applications in patients with RCC.
Identifiants
pubmed: 37606040
pii: 167712
doi: 10.1172/jci.insight.167712
pmc: PMC10543709
doi:
pii:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Pathol Int. 2019 Sep;69(9):511-518
pubmed: 31397525
J Clin Invest. 2018 Nov 1;128(11):4804-4820
pubmed: 30137025
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
J Immunother Cancer. 2017 Feb 21;5:18
pubmed: 28239471
Nucleic Acids Res. 2020 Jul 2;48(W1):W449-W454
pubmed: 32406916
Front Oncol. 2021 Apr 22;11:657187
pubmed: 33968761
N Engl J Med. 2016 Jun 30;374(26):2542-52
pubmed: 27093365
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
J Gen Virol. 2008 Feb;89(Pt 2):567-572
pubmed: 18198388
Nat Commun. 2020 Mar 10;11(1):1293
pubmed: 32157095
Nature. 2014 Nov 27;515(7528):577-81
pubmed: 25428507
Virology. 2011 Mar 15;411(2):273-87
pubmed: 21251689
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Nat Biotechnol. 2022 Feb;40(2):175-188
pubmed: 34635837
Sci Adv. 2022 Jan 28;8(4):eabj3671
pubmed: 35080970
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
J Immunoassay Immunochem. 2011;32(2):93-102
pubmed: 21391046
Nat Biotechnol. 2015 Nov;33(11):1152-8
pubmed: 26372948
Retrovirology. 2016 Jan 22;13:7
pubmed: 26800882
JCI Insight. 2018 Aug 23;3(16):
pubmed: 30135306
Cancer Res. 2012 Apr 1;72(7):1642-50
pubmed: 22311675
Nature. 2001 Feb 15;409(6822):860-921
pubmed: 11237011
JCI Insight. 2021 Jul 22;6(14):
pubmed: 34185709
Nat Commun. 2016 Nov 21;7:13404
pubmed: 27869121
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Sci Transl Med. 2018 Dec 5;10(470):
pubmed: 30518613
Cancer Res. 2016 Apr 15;76(8):2177-85
pubmed: 26862115
Cancer Immunol Res. 2021 Nov;9(11):1342-1353
pubmed: 34433589
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Cancer Res. 2002 Oct 1;62(19):5510-6
pubmed: 12359761